Relay Therapeutics Inc
RLAY3.705USD
+0.345+10.27%
Horário de mercado （ET）Cotações atrasadas em 15 min
631.64MValor de mercado
PerdaP/L TTM
Mais detalhes de Relay Therapeutics Inc Empresa
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Informações da empresa
Código da empresaRLAY
Nome da EmpresaRelay Therapeutics Inc
Data de listagemJul 16, 2020
CEODr. Sanjiv K. Patel, M.D.
Número de funcionários261
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 16
Endereço60 Hampshire Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02139
Telefone16173708837
Sitehttps://relaytx.com/
Código da empresaRLAY
Data de listagemJul 16, 2020
CEODr. Sanjiv K. Patel, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams
Mr. Brian R. Adams
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
173.28K
-8.97%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams
Mr. Brian R. Adams
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
173.28K
-8.97%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
7.68M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 18 de mai
Atualizado em: dom, 18 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
SB Investment Advisers (UK) Limited
16.28%
Point72 Asset Management, L.P.
6.32%
BlackRock Institutional Trust Company, N.A.
6.29%
Commodore Capital LP
5.83%
The Vanguard Group, Inc.
5.47%
Other
59.81%
Investidores
Investidores
Proporção
SB Investment Advisers (UK) Limited
16.28%
Point72 Asset Management, L.P.
6.32%
BlackRock Institutional Trust Company, N.A.
6.29%
Commodore Capital LP
5.83%
The Vanguard Group, Inc.
5.47%
Other
59.81%
Tipos de investidores
Investidores
Proporção
Hedge Fund
33.84%
Investment Advisor
30.76%
Private Equity
17.05%
Investment Advisor/Hedge Fund
15.09%
Sovereign Wealth Fund
3.37%
Research Firm
2.12%
Individual Investor
1.48%
Venture Capital
0.96%
Family Office
0.37%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
457
180.97M
105.56%
-7.64M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
2023Q1
398
137.34M
113.25%
-2.03M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
SB Investment Advisers (UK) Limited
27.90M
16.28%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
10.83M
6.32%
+9.23M
+579.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.79M
6.29%
-75.94K
-0.70%
Mar 31, 2025
Commodore Capital LP
10.00M
5.83%
+10.00M
--
May 08, 2025
The Vanguard Group, Inc.
12.08M
7.04%
-2.92M
-19.50%
Mar 31, 2025
Casdin Capital, LLC
9.10M
5.31%
+150.00K
+1.68%
Mar 31, 2025
Tang Capital Management, LLC
8.07M
4.71%
--
--
Mar 31, 2025
Bellevue Asset Management AG
7.38M
4.3%
--
--
Mar 31, 2025
Norges Bank Investment Management (NBIM)
5.78M
3.37%
+2.46M
+74.19%
Dec 31, 2024
State Street Global Advisors (US)
5.16M
3.01%
-120.53K
-2.28%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
TrueShares Technology, AI & Deep Learning ETF
0.47%
Tema Oncology ETF
0.42%
ALPS Medical Breakthroughs ETF
0.4%
JPMorgan Fundamental Data Science Small Core ETF
0.18%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
Avantis US Small Cap Equity ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.9%
TrueShares Technology, AI & Deep Learning ETF
Proporção0.47%
Tema Oncology ETF
Proporção0.42%
ALPS Medical Breakthroughs ETF
Proporção0.4%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.18%
SPDR S&P Biotech ETF
Proporção0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.09%
Avantis US Small Cap Equity ETF
Proporção0.07%
ProShares Ultra Nasdaq Biotechnology
Proporção0.07%
Invesco Nasdaq Biotechnology ETF
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
